Everything we know about apitoxin we learned by writing it down. Search by molecule, system, or clinical topic.
How a 26-amino-acid peptide became the most studied molecule in clinical apitherapy — and why purity below 99.9% is medically meaningless.
The 18-residue peptide that blocks SK channels with surgical specificity — and why it is the unsung half of every BSerum dose.
PLA₂ is the immunologically loudest component of bee venom. Most apitherapy programmes try to remove it. We standardise it to 0.6% — and the data explains why.
Inside the closed-loop control system that adjusts every BSerum dose in real time across 14 biomarkers — and why the model does not get to decide alone.
The registry behind the headline number — what we measured, how we adjudicated, and what we still do not know.
Why the topical protocol works on conditions we historically treated systemically — and what the dermal microenvironment is actually doing.
Why our 30-day initiation looks the way it does — and the four things we changed after the first 400 patients told us we were wrong.
A short, blunt guide to the marketing claims, folk remedies, and overconfident influencer pitches that have nothing to do with clinical apitherapy.
What our classification actually means, what it does not mean, and what we are working toward in 2026.
Three anonymised patient journeys reconstructed entirely from signed session telemetry — no testimonials, no editing, just the data and what it shows.